Hovione & iBET Announce the Establishment of a Venture in Cell & Gene Therapy Solutions

Hovione and iBET recently announced the official establishment of ​​​​​​ViSync Technologies as a jointly owned venture. The creation of this new company, headquartered in the Lisbon area of Portugal, illustrates the parent companies´ commitment to partnership and joint innovation. ViSync will aim to develop innovative solutions to address the unmet technical needs of pharmaceutical companies in the cell and gene therapy space, leveraging Hovione’s extensive expertise in pharmaceutical development, Particle Engineering and industrialization of pharmaceutical technologies and iBET’s cutting-edge research in biotechnological sciences. One of the first focus areas of ViSync will be to develop technologies that improve delivery and stabilization of new modality therapies.

“We are delighted to join forces with iBET – a leading R&D organization in Biotechnology and Life Sciences – in the establishment of ViSync,” said Jean-Luc Herbeaux, Hovione’s CEO. “By combining Hovione´s expertise in drug formulation, manufacturing process development and scale up with iBET´s broad understanding of new modalities, we aim to devise new solutions to help pharma companies launch innovative medicines and improve health outcomes for patients.”

“The creation of ViSync marks a significant milestone for iBET,” added Paula Alves, CEO of iBET. “By combining our cutting-edge biotechnological research in the cell and gene therapy fields with Hovione’s extensive pharmaceutical development expertise, we are well-positioned to develop innovative approaches for targeted delivery and stabilization of new modality therapies. We are excited about the potential of ViSync to drive substantial advancements and deliver significant benefits to patients worldwide.”

Hovione is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations. As a​​​​​ Contract Development and Manufacturing Organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, Hovione offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices. Hovione’s culture is based on innovation, quality and dependability. Hovione is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.

iBET is a private non-profit institution devoted to biotechnology research, with 35 years of experience creating and transferring knowledge to the global biopharma and biotech sectors. iBET’s core expertise lies on the development of bioprocesses and analytical tools for Advanced Therapeutic Medicinal Products (ATMPs), including cell and gene therapies, vaccines, antibodies and other innovative therapeutic products. Leveraged by the emerging areas of Data Science and Translational Immunology, we offer bespoke R&D services from early-stage R&D to GMP manufacturing. iBET’s infrastructure comprises cutting-edge laboratories, a GMP certified Analytical Services Unit, and a Late-Stage R&D and Bioproduction Unit, covering upstream and downstream process development, bioanalytical tools for critical quality attribute monitoring, to scale-up and tech transfer. iBET also hosts satellite laboratories of major pharmaceutical companies and serves as an incubation platform for start-up/spin-off companies. iBET is driven by its innovative and agile culture of continuous improvement and a strong sense of ambition, ownership and commitment in developing and delivering the best solutions to our stakeholders